DK3248986T3 - Variable immunoglobulindomæner - Google Patents

Variable immunoglobulindomæner Download PDF

Info

Publication number
DK3248986T3
DK3248986T3 DK17178990.2T DK17178990T DK3248986T3 DK 3248986 T3 DK3248986 T3 DK 3248986T3 DK 17178990 T DK17178990 T DK 17178990T DK 3248986 T3 DK3248986 T3 DK 3248986T3
Authority
DK
Denmark
Prior art keywords
immunoglobulin domains
variable immunoglobulin
variable
domains
immunoglobulin
Prior art date
Application number
DK17178990.2T
Other languages
English (en)
Inventor
Marie-Ange Buyse
Carlo Boutton
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Application granted granted Critical
Publication of DK3248986T3 publication Critical patent/DK3248986T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK17178990.2T 2014-05-16 2015-05-13 Variable immunoglobulindomæner DK3248986T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461994552P 2014-05-16 2014-05-16
US201461014015P 2014-06-18 2014-06-18
US201462014015P 2014-06-18 2014-06-18
US201462040167P 2014-08-21 2014-08-21
US201462047560P 2014-09-08 2014-09-08
US201562133600P 2015-03-16 2015-03-16
EP15722211.8A EP3143042B1 (en) 2014-05-16 2015-05-13 Immunoglobulin variable domains

Publications (1)

Publication Number Publication Date
DK3248986T3 true DK3248986T3 (da) 2022-04-04

Family

ID=91193230

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15722211.8T DK3143042T3 (da) 2014-05-16 2015-05-13 Forbedrede variable immunoglobulindomæner
DK17178990.2T DK3248986T3 (da) 2014-05-16 2015-05-13 Variable immunoglobulindomæner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15722211.8T DK3143042T3 (da) 2014-05-16 2015-05-13 Forbedrede variable immunoglobulindomæner

Country Status (25)

Country Link
US (10) US20170121399A1 (da)
EP (4) EP3143042B1 (da)
JP (6) JP7325928B2 (da)
KR (5) KR20230054503A (da)
CN (3) CN106661100A (da)
AU (6) AU2015261536B2 (da)
BR (2) BR112016026773A2 (da)
CA (2) CA2948076A1 (da)
DK (2) DK3143042T3 (da)
ES (2) ES2815572T3 (da)
HR (2) HRP20220400T1 (da)
HU (2) HUE058008T2 (da)
IL (6) IL299282B1 (da)
LT (2) LT3143042T (da)
MX (4) MX2016014926A (da)
NZ (1) NZ726448A (da)
PH (1) PH12016502282A1 (da)
PL (2) PL3248986T3 (da)
PT (2) PT3143042T (da)
RS (2) RS60717B1 (da)
RU (2) RU2746738C2 (da)
SG (3) SG11201609162SA (da)
SI (2) SI3143042T1 (da)
WO (1) WO2015173325A2 (da)
ZA (5) ZA201607587B (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CA3142288A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG11201609162SA (en) * 2014-05-16 2016-12-29 Ablynx Nv Improved immunoglobulin variable domains
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
CN108431039B (zh) * 2015-11-12 2022-06-28 埃博灵克斯股份有限公司 改进的p2x7受体结合剂和包含其的多肽
NO2768984T3 (da) * 2015-11-12 2018-06-09
JP7195142B2 (ja) 2015-11-13 2022-12-23 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
TWI754621B (zh) 2015-11-18 2022-02-11 美商默沙東藥廠 Pd1及／或 lag3結合劑
WO2017087587A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. PD1/CTLA4 Binders
UA125337C2 (uk) 2015-11-18 2022-02-23 Мерк Шарп І Доум Корп. Ctla4-зв'язувальні речовини
CN114605530A (zh) * 2015-11-18 2022-06-10 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
CN108699151B (zh) 2016-02-12 2022-08-12 埃博灵克斯股份有限公司 用于制备免疫球蛋白单可变结构域的方法
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
WO2017220645A1 (en) 2016-06-23 2017-12-28 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
US11840569B2 (en) 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
RU2022101604A (ru) 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
SG10202108972RA (en) 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
BR112019014600A2 (pt) 2017-01-17 2020-02-18 Ablynx N.V. Ligantes de albumina sérica melhorados
CN111032695B (zh) 2017-06-02 2024-06-25 默克专利股份有限公司 结合adamts的免疫球蛋白
US11155607B2 (en) 2017-07-19 2021-10-26 Vib Vzw Serum albumin binding agents
EP3704160A1 (en) 2017-10-31 2020-09-09 VIB vzw Novel antigen-binding chimeric proteins and methods and uses thereof
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
KR20220122652A (ko) 2019-12-06 2022-09-02 아블린쓰 엔.브이. TNFα 및 IL-23을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
CA3163764A1 (en) 2019-12-06 2021-06-10 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
US20210188965A1 (en) 2019-12-09 2021-06-24 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
EP4077372A1 (en) 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
CN115698047A (zh) 2020-02-25 2023-02-03 非营利性组织佛兰芒综合大学生物技术研究所 富含亮氨酸的重复激酶2变构调节剂
TW202204423A (zh) 2020-03-30 2022-02-01 比利時商艾伯霖克斯公司 用於產生和純化多價免疫球蛋白單可變域的方法
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
BR112023005273A2 (pt) 2020-09-25 2023-04-25 Ablynx Nv Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a il-13 e ox40l
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
CA3201219A1 (en) 2020-12-04 2022-06-09 Mir Ali Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
TW202239763A (zh) 2020-12-18 2022-10-16 比利時商艾伯霖克斯公司 包含靶向ＩＬ－６和ＴＮＦ－α的免疫球蛋白單可變結構域的多肽
MX2023007299A (es) 2020-12-18 2023-07-04 Ablynx Nv Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta.
TW202241947A (zh) 2020-12-18 2022-11-01 比利時商艾伯霖克斯公司 包含靶向磷脂醯肌醇蛋白聚糖—３和ｔ細胞受體的免疫球蛋白單可變結構域的多肽
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
IL304929A (en) 2021-02-05 2023-10-01 Vib Vzw [Be/Be Sarbevirus binders
IL305318A (en) 2021-02-19 2023-10-01 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022206900A1 (zh) * 2021-04-01 2022-10-06 江苏先声药业有限公司 抗人血清白蛋白(hsa)的纳米抗体及其应用
WO2023016828A2 (en) 2021-07-30 2023-02-16 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
WO2023093899A1 (zh) * 2021-11-29 2023-06-01 江苏恒瑞医药股份有限公司 经修饰的蛋白或多肽
CA3242445A1 (en) 2021-12-17 2023-06-22 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting tcras, cd33 and cd123
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
EP4273162A1 (en) * 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2023214047A1 (en) 2022-05-06 2023-11-09 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2023222825A1 (en) 2022-05-18 2023-11-23 Vib Vzw Sarbecovirus spike s2 subunit binders
US20240002331A1 (en) 2022-06-08 2024-01-04 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
TW202415678A (zh) 2022-06-14 2024-04-16 比利時商艾伯霖克斯公司 靶向ｔ細胞受體的免疫球蛋白單可變結構域
WO2024023271A1 (en) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024137731A2 (en) 2022-12-21 2024-06-27 Genzyme Corporation Anti‑pd‑1×4‑1bb binding proteins
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2024168279A2 (en) 2023-02-10 2024-08-15 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
ES2325541T3 (es) 1992-08-21 2009-09-08 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
NZ506453A (en) 1998-02-19 2003-02-28 Xcyte Therapies Inc Compositions and methods for regulating lymphocyte activation
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
WO2002057445A1 (en) * 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
CN1642982A (zh) 2001-07-26 2005-07-20 唐诚公司 活化或抑制类Toll受体9的试剂
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
CA2492092A1 (en) 2002-06-28 2004-01-08 Greg Winter Immunoglobin single variant antigen-binding domains and dual-specific constructs
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
BRPI0316092B8 (pt) 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US9028816B2 (en) 2003-01-10 2015-05-12 Ablynx N.V. Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
CA2569240A1 (en) 2004-06-01 2005-12-15 Domantis Limited Drug fusion comprising a polypeptide drug and an immunoglobulin heavy chain variable domain specific for serum albumin
JP5113523B2 (ja) 2004-10-13 2013-01-09 アブリンクス ナームローゼ フェンノートシャップ アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド
EP2769990A3 (en) 2004-12-02 2015-02-25 Domantis Limited Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
CN101133084A (zh) 2004-12-02 2008-02-27 多曼蒂斯有限公司 采用白细胞介素-1ⅰ型受体拮抗剂治疗呼吸道疾病的方法
EP1888641B1 (en) 2005-05-18 2011-12-14 Ablynx N.V. Serum albumin binding proteins
JP4986997B2 (ja) 2005-05-20 2012-07-25 アブリンクス エン．ヴェー． 凝集媒介障害の治療における改良ナノボディ（商標）
WO2006129843A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2007063308A2 (en) 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
US20080311111A1 (en) 2005-12-01 2008-12-18 Drew Philip D Competitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
EP2097449A1 (en) 2006-12-05 2009-09-09 Ablynx N.V. Peptides capable of binding to serum proteins
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
CN104231082B (zh) 2007-05-24 2018-12-21 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
EP2158315B1 (en) 2007-06-25 2016-03-23 ESBATech, an Alcon Biomedical Research Unit LLC Methods of modifying antibodies, and modified antibodies with improved functional properties
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2009121804A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
WO2009138494A2 (en) * 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
EP2285833B1 (en) 2008-05-16 2014-12-17 Ablynx N.V. AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042815A2 (en) 2008-10-09 2010-04-15 Duke University Vhh antibody fragments for use in the detection and treatment of cancer
BRPI1013588A2 (pt) 2009-03-27 2016-04-19 Glaxo Group Ltd composição
AU2010243551B2 (en) 2009-04-30 2015-03-26 Ablynx Nv Method for the production of domain antibodies
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
HUE051430T2 (hu) 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
EP2486056A1 (en) 2009-10-09 2012-08-15 Ablynx N.V. Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
EP3309176A1 (en) 2009-12-14 2018-04-18 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and therapeutic use
JP5914353B2 (ja) * 2009-12-23 2016-05-11 エスバテック − ア ノバルティス カンパニー エルエルシー 免疫原性を減少させるための方法
JP5826194B2 (ja) 2010-03-03 2015-12-02 アブリンクス ナームローゼ フェンノートシャップ 二パラトープ性ａ−ベータ結合ポリペプチド
EP2552962B1 (en) 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
JP2013525408A (ja) 2010-04-30 2013-06-20 アブリンクス エン．ヴェー． ヘテロ二量体サイトカインｉｌ−２３のｐ１９サブユニットに指向性を有するナノボディのアミノ酸配列
EP2571901B1 (en) 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
WO2011161266A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
JP2013145769A (ja) 2010-08-04 2013-07-25 Kri Inc 異方性希土類ボンド磁石とその製造方法
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
US20130310281A1 (en) * 2011-02-02 2013-11-21 Glaxo Group Limited Novel antigen binding proteins
US20150158948A9 (en) 2011-03-28 2015-06-11 Francis Descamps Bispecific anti-cxcr7 immunoglobulin single variable domains
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CA3142288A1 (en) * 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
IN2014CN00437A (da) 2011-06-23 2015-04-03 Ablynx Nv
PT2723771T (pt) 2011-06-23 2019-12-11 Ablynx Nv Proteínas de ligação à albumina sérica
US20130019175A1 (en) * 2011-07-14 2013-01-17 Microsoft Corporation Submenus for context based menu system
AU2012296961B2 (en) 2011-08-17 2017-02-16 Glaxo Group Limited Modified proteins and peptides
JP6219287B2 (ja) 2011-09-30 2017-10-25 アブリンクス エン．ヴェー． ｃ−Ｍｅｔに関連する生物学的物質
PL3216871T3 (pl) 2011-10-17 2022-03-21 Regeneron Pharmaceuticals, Inc. Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
MY168748A (en) 2012-01-31 2018-11-30 Regeneron Pharma Anti-asic1 antibodies and uses thereof
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
JP2015531350A (ja) 2012-09-13 2015-11-02 ノバルティス アーゲー 末端修飾を有する抗原結合分子
US9667316B2 (en) 2013-05-17 2017-05-30 The Boeing Company Aircraft data transmission using phase separation
SG11201609162SA (en) 2014-05-16 2016-12-29 Ablynx Nv Improved immunoglobulin variable domains
JP6936797B2 (ja) 2015-10-30 2021-09-22 アブリンクス エン．ヴェー． Ｉｌ−２３に対するポリペプチド
CN108431039B (zh) 2015-11-12 2022-06-28 埃博灵克斯股份有限公司 改进的p2x7受体结合剂和包含其的多肽
NO2768984T3 (da) 2015-11-12 2018-06-09
JP7195142B2 (ja) 2015-11-13 2022-12-23 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
CN114605530A (zh) 2015-11-18 2022-06-10 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
WO2017087587A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. PD1/CTLA4 Binders
UA125337C2 (uk) 2015-11-18 2022-02-23 Мерк Шарп І Доум Корп. Ctla4-зв'язувальні речовини
TWI754621B (zh) 2015-11-18 2022-02-11 美商默沙東藥廠 Pd1及／或 lag3結合劑
BR112019014600A2 (pt) 2017-01-17 2020-02-18 Ablynx N.V. Ligantes de albumina sérica melhorados
KR20220122652A (ko) 2019-12-06 2022-09-02 아블린쓰 엔.브이. TNFα 및 IL-23을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
AR120698A1 (es) * 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
TW202239763A (zh) * 2020-12-18 2022-10-16 比利時商艾伯霖克斯公司 包含靶向ＩＬ－６和ＴＮＦ－α的免疫球蛋白單可變結構域的多肽

Also Published As

Publication number Publication date
EP3702369A1 (en) 2020-09-02
IL299282B1 (en) 2024-05-01
RU2018120744A3 (da) 2022-01-28
AU2020202570A1 (en) 2020-05-07
CN113717280A (zh) 2021-11-30
PL3248986T3 (pl) 2022-05-16
EP3693386A1 (en) 2020-08-12
EP3248986A3 (en) 2017-12-20
ZA202004759B (en) 2022-08-31
CA2948076A1 (en) 2015-11-19
LT3248986T (lt) 2022-03-25
US20210269515A1 (en) 2021-09-02
WO2015173325A2 (en) 2015-11-19
IL311293A (en) 2024-05-01
US11485778B2 (en) 2022-11-01
AU2020202855A1 (en) 2020-05-21
JP2024041939A (ja) 2024-03-27
HUE050007T2 (hu) 2020-11-30
KR20230054503A (ko) 2023-04-24
ZA202100742B (en) 2022-09-28
JP2021006563A (ja) 2021-01-21
IL295534A (en) 2022-10-01
EP3143042A2 (en) 2017-03-22
US11319364B2 (en) 2022-05-03
US20220251183A1 (en) 2022-08-11
US20200231662A1 (en) 2020-07-23
PH12016502282A1 (en) 2017-02-13
JP2021130681A (ja) 2021-09-09
US20210261653A1 (en) 2021-08-26
RU2016149463A3 (da) 2018-07-04
JP7098439B2 (ja) 2022-07-11
JP2018162297A (ja) 2018-10-18
IL259972A (en) 2018-07-31
RS63085B1 (sr) 2022-04-29
JP7471987B2 (ja) 2024-04-22
AU2022279374A1 (en) 2023-01-19
HUE058008T2 (hu) 2022-06-28
SI3143042T1 (sl) 2020-08-31
US11312764B2 (en) 2022-04-26
EP3248986B1 (en) 2022-01-26
PT3143042T (pt) 2020-09-01
SG11201609162SA (en) 2016-12-29
IL259972B (en) 2021-04-29
LT3143042T (lt) 2020-07-27
JP2017518072A (ja) 2017-07-06
WO2015173325A3 (en) 2016-02-18
JP7454525B2 (ja) 2024-03-22
AU2015261536B2 (en) 2020-05-07
AU2022279373A1 (en) 2023-01-19
US20170121399A1 (en) 2017-05-04
MX2018007581A (es) 2020-11-12
MX2021007020A (es) 2021-08-05
WO2015173325A8 (en) 2016-12-29
US20220332806A1 (en) 2022-10-20
JP2024069377A (ja) 2024-05-21
MX2023010731A (es) 2023-09-20
AU2015261536A1 (en) 2016-11-17
BR112016026773A2 (pt) 2017-12-12
US20210087261A1 (en) 2021-03-25
US20220135657A9 (en) 2022-05-05
RU2016149463A (ru) 2018-06-19
SG10201810124PA (en) 2018-12-28
IL248636B (en) 2022-12-01
US11708404B2 (en) 2023-07-25
US11220539B2 (en) 2022-01-11
US20220119512A1 (en) 2022-04-21
RU2018120744A (ru) 2018-11-15
ES2815572T3 (es) 2021-03-30
ZA202004758B (en) 2022-08-31
MX2016014926A (es) 2017-05-09
PT3248986T (pt) 2022-04-05
KR20230053002A (ko) 2023-04-20
US20210269514A1 (en) 2021-09-02
SG10201805288QA (en) 2018-07-30
RU2021107470A (ru) 2021-05-17
AU2020202855B2 (en) 2022-12-08
AU2020202570B2 (en) 2022-12-08
JP7325928B2 (ja) 2023-08-15
CA3175002A1 (en) 2015-11-19
US11312765B2 (en) 2022-04-26
NZ726448A (en) 2023-02-24
ZA202004757B (en) 2022-08-31
ES2912069T3 (es) 2022-05-24
US20220332807A1 (en) 2022-10-20
AU2018204226A1 (en) 2018-07-05
ZA201607587B (en) 2022-05-25
PL3143042T3 (pl) 2020-11-16
CN109053885A (zh) 2018-12-21
IL281755B1 (en) 2023-01-01
CN106661100A (zh) 2017-05-10
RS60717B1 (sr) 2020-09-30
IL281755B2 (en) 2023-05-01
EP3248986A2 (en) 2017-11-29
RU2746738C2 (ru) 2021-04-20
KR20230145503A (ko) 2023-10-17
DK3143042T3 (da) 2020-08-31
IL281755A (en) 2021-05-31
IL248636B2 (en) 2023-04-01
IL248636A0 (en) 2017-01-31
US11485777B2 (en) 2022-11-01
HRP20200966T1 (hr) 2020-10-16
SI3248986T1 (sl) 2022-04-29
EP3143042B1 (en) 2020-06-10
HRP20220400T1 (hr) 2022-05-27
BR122018009619B1 (pt) 2024-01-02
KR20170002645A (ko) 2017-01-06
KR20180091115A (ko) 2018-08-14
IL299282A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
IL281755A (en) Enhanced variable complexes of immunoglobulins
NL301117I1 (nl) trastuzumab deruxtecan
DK3344654T3 (da) Anti-lag-3-antistoffer
BR112017001385A2 (pt) anticorpos anti-pd-1
DK3560954T3 (da) Modificeret j-kæde
KR20180085002A (ko) 인간화된 항-cll-1 항체
DK3131928T3 (da) Trifunktionelt antigenbindende molekyle
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
UA30845S (uk) Закривальний засіб
DK3250593T3 (da) Anti-transthyretin-antistoffer
DOS2016000090S (es) Cierre
DK3551355T3 (da) Immobiliseret indsats
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3
DK3484921T3 (da) Anti-IL-22R antistoffer
DK3795591T3 (da) Cys80-konjugerede immunoglobuliner
DK3436447T3 (da) Isoquinolinyl-triazolon-komplekser
DE112014006280A5 (de) Kraftfahrzeugverschluss
DK3219863T3 (da) Kombinationskloset
UA34226S (uk) Водостічна труба
BR112017002234A2 (pt) anticorpos anti-pd-l1
BR302014001186S1 (pt) Configuração aplicada em lancheira
ES1127005Y (es) Aparato vinificador multifuncional